

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/264032 A2

(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/444 (2006.01)

(21) International Application Number:

PCT/US2024/035216

(22) International Filing Date:

24 June 2024 (24.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/509,699 22 June 2023 (22.06.2023) US

(71) Applicant: **VERALOX THERAPEUTICS INC.**
[US/US]; 321 Ballenger Center Drive, Suite 125, Frederick,
Maryland 21703 (US).

(72) Inventors: **MALONEY, David**; c/o Veralox Therapeutics Inc., 321 Ballenger Center Drive, Suite 125, Frederick, Maryland 21703 (US). **BOXER, Matthew**; c/o Veralox Therapeutics Inc., 321 Ballenger Center Drive, Suite 125, Frederick, Maryland 21703 (US).

(74) Agent: **SCHEIDEMAN, Matthew H.** et al.; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2024/264032 A2

(54) Title: COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES

(57) Abstract: The present disclosure provides compounds, compositions, and uses thereof, for example, in the treatment of 12 lipoxigenase (12-LOX) mediated diseases.